Gelonghui, March 27 | Jinxin Reproduction (01951.HK) announced that for the year ended December 31, 2023, the Group's revenue was approximately RMB 2,789 million, an increase of 18.0% over the previous year. Net profit was approximately RMB 347 million, up 194.2% year on year. Basic earnings per share was RMB 0.13. The adjusted basic earnings per non-IFRS share for the year ended 31 December 2023 (4) was RMB 0.18. The Board recommended the payment of a final dividend of HK5.95 HK cents per share for the year ended 31 December 2023 (year ended 31 December 2022: zero).
In 2023, the company gradually recovered from the impact of the COVID-19 pandemic. According to its long-term business development strategy, the company continues to optimize and enhance its strength in all aspects, including clinical standards, talent training, scientific research and innovation, discipline construction, organizational construction, supply chain management, capacity expansion, informatization construction, and business integration. This lays the foundation for business recovery and growth in the post-pandemic era. Over the past year, the company has also achieved remarkable results in these areas.
In the assisted reproduction business, the company has always been committed to improving the success rate of the company's fertility treatment, improving the patient experience, and strengthening the company's market reputation and influence in the ARS industry. In terms of talent, the company continues to strengthen the strength of the medical team through recruitment and internal training; in terms of research, the company further increases investment in R&D teams and research activities to improve clinical transformation and promote the improvement of clinical standards; in terms of expertise, the company continuously develops and strengthens specialty specialties, specialists and specialties to strengthen the company's advantages in ARS; in terms of operation and management, the company combines refined operation and innovative initiatives to improve the efficiency of hospital management; in terms of business expansion, the company expands the production capacity of existing hospitals and seizes the development potential of the industry.
In terms of informatization construction, the Group has implemented a digital platform and a proprietary customer relationship management system in the Group's medical facility network to promote the construction of information-based smart hospitals, digitize patient management, appointment and payment processes, create a more efficient and enjoyable medical experience, and enhance the overall operation of the hospital. Such initiatives have further strengthened the company's leading edge and market leadership position in the assisted reproduction business in Greater China and the US.
Since successfully completing the acquisition of Sichuan Jinxin Xinan Hospital (Jingxiu Campus) in November 2021, the company has continued to use the company's advantages in ARS (as the company's core business) to expand full-cycle childbearing services, including pregnancy preparation, IVF, prenatal, production, postpartum and menopause services, so that the company can achieve sustainable high growth in the future. The Group completed an internal restructuring in December 2022, enabling Sichuan Jinxin Xinan Hospital (Jingxiu Campus) to further expand its scope of services (including obstetrics and gynecology medical services) and provide medical services involving molecular genetic services in accordance with applicable Chinese law.